磺达肝癸钠相关性血小板减少症
Fondaparinux-associated Thrombocytopenia.
作者信息
Malik Jahanzeb, Javed Nismat, Kamin Matiullah
机构信息
Dr. Jahanzeb Malik, Rawalpindi Institute of Cardiology, Rawalpindi, Pakistan.
Dr. Nismat Javed, Shifa College of Medicine, Shifa Tameer-e-Millat University, Islamabad, Pakistan.
出版信息
Pak J Med Sci. 2021 Mar-Apr;37(2):598-599. doi: 10.12669/pjms.37.2.3522.
Abstract
Heparin-induced thrombocytopenia (HIT) is an immune-mediated condition causing thrombocytopenia and paradoxical thrombosis after exposure to heparin or low-molecular-weight heparin. It has been rarely reported by Fondaparinux, an artificial pentasaccharide similar to heparin. This manuscript presents a case of HIT associated with fondaparinux use.
摘要
肝素诱导的血小板减少症（HIT）是一种免疫介导的疾病，在接触肝素或低分子量肝素后可导致血小板减少和反常血栓形成。与肝素类似的人工合成五糖磺达肝癸钠引起HIT的情况鲜有报道。本文报告了1例与使用磺达肝癸钠相关的HIT病例。
相似文献
1
Fondaparinux-associated Thrombocytopenia.磺达肝癸钠相关性血小板减少症
Pak J Med Sci. 2021 Mar-Apr;37(2):598-599. doi: 10.12669/pjms.37.2.3522.
2
Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia.肝素诱导的血小板减少症（HIT）的临床特征及其与非 HIT 性血小板减少症的鉴别。
Thromb Haemost. 2016 Oct 28;116(5):813-822. doi: 10.1160/TH16-06-0435. Epub 2016 Sep 22.
3
Special considerations with fondaparinux therapy: heparin-induced thrombocytopenia and wound healing.磺达肝癸钠治疗的特殊注意事项：肝素诱导的血小板减少症和伤口愈合。
Pharmacotherapy. 2004 Jul;24(7 Pt 2):88S-94S. doi: 10.1592/phco.24.10.88s.36122.
4
Fondaparinux-associated heparin-induced thrombocytopenia.磺达肝癸钠相关性肝素诱导的血小板减少症。
Proc (Bayl Univ Med Cent). 2012 Jan;25(1):13-5. doi: 10.1080/08998280.2012.11928771.
5
Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.磺达肝癸钠用于血栓栓塞治疗及肝素诱导的血小板减少症的预防。
Ann Pharmacother. 2006 Jul-Aug;40(7-8):1383-7. doi: 10.1345/aph.1G738. Epub 2006 Jun 20.
6
[Successful treatment with fondaparinux in heparin-induced thrombocytopenia and thrombosis].磺达肝癸钠成功治疗肝素诱导的血小板减少症和血栓形成
Medicina (B Aires). 2015;75(5):307-10.
7
Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients.磺达肝癸钠作为心脏手术后患者肝素诱导的血小板减少症管理的安全替代药物。
J Cardiothorac Vasc Anesth. 2014 Aug;28(4):1008-12. doi: 10.1053/j.jvca.2013.09.008. Epub 2014 Jan 16.
8
Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.使用非标签外或批准的抗凝剂治疗肝素诱导的血小板减少症。
J Am Coll Cardiol. 2017 Nov 28;70(21):2636-2648. doi: 10.1016/j.jacc.2017.09.1099.
9
Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.磺达肝癸钠治疗急性肝素诱导的血小板减少症：单中心经验。
Clin Appl Thromb Hemost. 2010 Dec;16(6):663-7. doi: 10.1177/1076029609347900. Epub 2009 Oct 13.
10
Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.低剂量磺达肝癸钠用于危重症患者疑似肝素诱导的血小板减少症
Neth J Med. 2007 Mar;65(3):101-8.
引用本文的文献
1
Fondaparinux Failure in Heparin-Induced Thrombocytopenia With Acute Limb Ischemia: A Case Report and Literature Review.磺达肝癸钠治疗肝素诱导的血小板减少症伴急性肢体缺血失败：一例报告及文献综述
Cureus. 2025 Jun 9;17(6):e85627. doi: 10.7759/cureus.85627. eCollection 2025 Jun.
2
Safety comparisons among different subcutaneous anticoagulants for venous thromboembolism using FDA adverse event reporting system.使用美国食品药品监督管理局不良事件报告系统对不同皮下抗凝剂治疗静脉血栓栓塞的安全性进行比较。
Sci Rep. 2025 May 16;15(1):17070. doi: 10.1038/s41598-025-01527-9.
3
Evaluating the immunogenicity of heparin and heparin derivatives by measuring their binding to platelet factor 4 using biolayer interferometry.通过生物膜干涉术测量肝素及肝素衍生物与血小板第4因子的结合，评估其免疫原性。
Front Mol Biosci. 2022 Aug 26;9:966754. doi: 10.3389/fmolb.2022.966754. eCollection 2022.
本文引用的文献
1
Detection of Platelet-Activating Antibodies Associated with Heparin-Induced Thrombocytopenia.与肝素诱导的血小板减少症相关的血小板活化抗体的检测
J Clin Med. 2020 Apr 24;9(4):1226. doi: 10.3390/jcm9041226.
2
Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis and Management.肝素诱导的血小板减少症：病理生理学、诊断与管理
Cureus. 2020 Mar 24;12(3):e7385. doi: 10.7759/cureus.7385.
3
Diagnosis and management of heparin-induced thrombocytopenia.肝素诱导的血小板减少症的诊断与管理
Anaesth Crit Care Pain Med. 2020 Apr;39(2):291-310. doi: 10.1016/j.accpm.2020.03.012. Epub 2020 Apr 13.
4
The paradox of heparin induced thrombocytopenia-thrombosis, the role of fondaparinux and the need for new therapeutic strategies.肝素诱导的血小板减少症-血栓形成的矛盾、磺达肝癸钠的作用及新治疗策略的必要性
Int Angiol. 2020 Aug;39(4):350-351. doi: 10.23736/S0392-9590.20.04364-3. Epub 2020 Mar 26.
5
Perioperative Bleeding in Patients With Acute Coronary Syndrome Treated With Fondaparinux Versus Low-Molecular-Weight Heparin Before Coronary Artery Bypass Grafting.在冠状动脉旁路移植术前接受磺达肝素钠与低分子肝素治疗的急性冠状动脉综合征患者的围手术期出血。
Am J Cardiol. 2019 Feb 15;123(4):565-570. doi: 10.1016/j.amjcard.2018.11.028. Epub 2018 Nov 24.
6
HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT.磺达肝癸钠预防相关的肝素诱导的血小板减少症：依赖磺达肝癸钠的血小板活化作为磺达肝癸钠诱导的肝素诱导的血小板减少症的标志物。
Thromb Haemost. 2014 Dec;112(6):1319-22. doi: 10.1160/TH14-08-0711. Epub 2014 Oct 16.
7
Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.疑似急性肝素诱导的血小板减少症（HIT）患者中频繁使用磺达肝癸钠的情况——来自德国肝素诱导血小板减少症（GerHIT）多中心注册研究的结果
Thromb Res. 2014 Jul;134(1):29-35. doi: 10.1016/j.thromres.2014.03.029. Epub 2014 Mar 18.
8
Heparin-induced thrombocytopenia: comparison between response to fondaparinux and lepirudin.肝素诱导的血小板减少症：磺达肝癸钠与来匹卢定的反应比较。
Int J Clin Pharm. 2011 Dec;33(6):997-1001. doi: 10.1007/s11096-011-9573-3. Epub 2011 Oct 16.
9
Thrombocytopenia during fondaparinux prophylaxis: HIT or something different?磺达肝癸钠预防期间的血小板减少症：是肝素诱导的血小板减少症还是其他情况？
Intern Emerg Med. 2010 Aug;5(4):361-3. doi: 10.1007/s11739-010-0379-4. Epub 2010 May 5.
10
Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.低分子量肝素引起的迟发性肝素诱导的血小板减少症在磺达肝癸钠预防期间出现。
Am J Hematol. 2008 Nov;83(11):876-8. doi: 10.1002/ajh.21273.
Zotero 插件